ChromaDex Corporation (CDXC)
NASDAQ: CDXC · IEX Real-Time Price · USD
2.775
+0.015 (0.54%)
At close: Jul 19, 2024, 4:00 PM
2.780
+0.005 (0.18%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
ChromaDex Revenue
ChromaDex had revenue of $83.17M in the twelve months ending March 31, 2024, with 7.52% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $22.15M. In the year 2023, ChromaDex had annual revenue of $83.57M with 15.99% growth.
Revenue (ttm)
$83.17M
Revenue Growth
+7.52%
P/S Ratio
2.52
Revenue / Employee
$784,594
Employees
106
Market Cap
209.62M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
Dec 31, 2019 | 46.29M | 14.73M | 46.69% |
Dec 31, 2018 | 31.56M | 10.36M | 48.85% |
Dec 30, 2017 | 21.20M | -463.65K | -2.14% |
Dec 31, 2016 | 21.66M | 3.78M | 21.13% |
Jan 2, 2016 | 17.88M | 2.57M | 16.79% |
Jan 3, 2015 | 15.31M | 5.15M | 50.71% |
Dec 28, 2013 | 10.16M | -1.45M | -12.48% |
Dec 29, 2012 | 11.61M | 3.50M | 43.12% |
Dec 31, 2011 | 8.11M | 546.24K | 7.22% |
Jan 1, 2011 | 7.57M | 1.79M | 30.95% |
Jan 2, 2010 | 5.78M | 1.27M | 28.22% |
Jan 3, 2009 | 4.51M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
HF Foods Group | 1.15B |
Whole Earth Brands | 548.00M |
Nature's Sunshine Products | 447.68M |
The Beauty Health Company | 393.12M |
Vasta Platform | 306.99M |
Forafric Global | 305.48M |
Lifeway Foods | 166.85M |
FitLife Brands | 58.51M |
CDXC News
- 5 days ago - ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August - Business Wire
- 20 days ago - ChromaDex to Join Russell 2000® Index - Business Wire
- 27 days ago - Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) - Business Wire
- 5 weeks ago - ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) - Business Wire
- 6 weeks ago - ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) - Business Wire
- 6 weeks ago - ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 - Business Wire
- 2 months ago - ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - Business Wire
- 2 months ago - ChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award - Business Wire